A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer

J. Veeraraghavan, C. De Angelis, R. Mao, T. Wang, S. Herrera, A. C. Pavlick, A. Contreras, P. Nuciforo, I. A. Mayer, A. Forero, R. Nanda, M. P. Goetz, Jenny C. Chang, A. C. Wolff, I. E. Krop, S. A.W. Fuqua, A. Prat, S. G. Hilsenbeck, B. Weigelt, J. S. Reis-FilhoC. Gutierrez, C. K. Osborne, M. F. Rimawi, R. Schiff

Research output: Contribution to journalArticle

16 Scopus citations

Fingerprint Dive into the research topics of 'A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences